Ectonucleotide pyrophosphatase/phosphodiesterase 1 deficiency, known as ENPP1 Deficiency, is a rare genetic disorder that disrupts the body’s ability to properly control calcium deposits and bone formation. The condition can be life-threatening in infants and causes serious complications throughout a patient’s lifetime, yet current treatment focuses on managing symptoms rather than addressing the root cause.

Understanding Treatment Goals in a Complex Disorder

When doctors talk about treating ENPP1 Deficiency, they are addressing a condition that changes as patients grow. The main goal of treatment depends heavily on when the disease appears and how severely it affects each person. In infants, the priority is often simply keeping the child alive, as roughly half of babies with this condition do not survive beyond six months of age due to severe heart and blood vessel problems. For those who survive infancy and progress into childhood, treatment shifts toward managing bone problems, growth difficulties, and preventing further complications. Adults with the condition face ongoing challenges with weak bones, painful joints, and calcification in soft tissues that continues to worsen over time.^[1]

The overarching aim in managing ENPP1 Deficiency is to improve quality of life by controlling symptoms, slowing disease progression, and helping patients maintain as much physical function as possible. Because this is a genetic disorder affecting a critical enzyme in the body, treatment must address multiple organ systems simultaneously. The enzyme called ENPP1 normally breaks down a substance called ATP to produce pyrophosphate (PPi), which prevents harmful calcium deposits from forming in soft tissues like blood vessels. When this enzyme doesn’t work properly, calcium builds up where it shouldn’t, while bones don’t mineralize properly and become weak.^[2]

Standard medical treatments approved by professional societies exist for managing individual symptoms, but these do not fix the underlying enzyme deficiency. Meanwhile, researchers are actively investigating new therapies in clinical trials, including experimental enzyme replacement treatments designed to restore what the body is missing. These investigational approaches represent hope for patients who currently have no approved disease-modifying therapy.^[1]

Standard Treatment Approaches

Currently, there are no therapies specifically approved to treat the root cause of ENPP1 Deficiency. Instead, doctors rely on supportive care measures that target individual symptoms and complications as they arise. This means that each patient receives a customized treatment plan based on which organs are affected and how severe the disease manifestations are at any given time.^[1]

For infants presenting with generalized arterial calcification of infancy (GACI), the immediate focus is on managing life-threatening cardiovascular complications. These babies often require intensive cardiac support, including medications to control blood pressure and heart failure. Some infants develop such severe narrowing of blood vessels that they experience heart attacks, strokes, or organ failure despite medical intervention. The medical team typically includes cardiologists, nephrologists, and metabolic specialists working together to stabilize the infant’s condition.^[1]

In children who survive the infant stage, the condition typically manifests as autosomal recessive hypophosphatemic rickets type 2 (ARHR2). This form of the disease involves abnormally low levels of phosphate in the blood, leading to bone softening and deformities. Standard treatment for hypophosphatemic rickets in general includes phosphate supplements given by mouth, usually several times daily, combined with active vitamin D (such as calcitriol). These supplements aim to raise blood phosphate levels to support proper bone mineralization. However, the effectiveness of these treatments in ENPP1 Deficiency specifically remains unclear, as the underlying problem involves more than just phosphate levels—the absence of PPi means that even when phosphate is available, bone formation may still be abnormal.^[3]

Phosphate supplementation must be carefully monitored because too much phosphate can worsen soft tissue calcification, one of the hallmark problems in ENPP1 Deficiency. This creates a difficult balancing act: doctors want to provide enough phosphate to support bone health but not so much that it accelerates calcium deposits in blood vessels and other soft tissues. Blood tests to monitor phosphate, calcium, and kidney function are typically performed regularly throughout treatment.^[3]

For adults, treatment often focuses on managing chronic pain and mobility problems caused by progressive joint calcification and bone weakness. This may include pain medications, physical therapy to maintain mobility and strength, and sometimes surgical procedures to address severe bone deformities or joint problems. Hearing loss, another common complication, may require hearing aids or other assistive devices. Adults also need ongoing monitoring for cardiovascular complications, as arterial calcification can continue to progress throughout life.^[1]

Physical therapy plays an important role across all age groups. For children, it helps address developmental delays, muscle weakness, and abnormal walking patterns caused by bone deformities. Exercises are designed to strengthen muscles, improve balance and coordination, and maintain joint flexibility. Adults benefit from physical therapy programs aimed at preserving independence and reducing the risk of falls and fractures from weak bones.^[17]

The duration of treatment extends throughout a patient’s entire lifetime, as ENPP1 Deficiency is a chronic genetic condition that does not resolve. Medication regimens, therapy schedules, and monitoring frequency change as patients age and develop new complications. Regular follow-up appointments with specialists—including cardiologists, endocrinologists, orthopedic surgeons, and audiologists—are essential to detect problems early and adjust treatment plans accordingly.^[3]

Side effects from standard treatments vary depending on which medications and interventions are used. Phosphate supplements commonly cause stomach upset, diarrhea, and nausea, which can make it difficult for patients to take them consistently. Vitamin D supplementation requires careful monitoring because excessive amounts can lead to high calcium levels in the blood, potentially worsening soft tissue calcification. Pain medications, particularly if used long-term, carry risks including stomach problems, kidney damage, or dependency issues. Surgical procedures to correct bone deformities involve typical surgical risks such as infection, bleeding, and anesthesia complications.^[3]

Investigational Treatments in Clinical Trials

The most promising experimental approach currently being studied for ENPP1 Deficiency is enzyme replacement therapy. This strategy aims to provide patients with a functioning version of the ENPP1 enzyme they lack, directly addressing the root cause of the disease rather than just managing symptoms. The lead investigational drug in this category is called INZ-701, a recombinant form of the ENPP1 enzyme being developed by Inozyme Pharma.^[1]

INZ-701 works by mimicking what the natural ENPP1 enzyme does in healthy people. When given to patients, it breaks down ATP in the bloodstream and extracellular spaces to generate pyrophosphate and adenosine monophosphate. The pyrophosphate then acts as a natural inhibitor of calcium crystal formation, potentially preventing harmful calcification in blood vessels and soft tissues. At the same time, by supporting normal mineral metabolism, the treatment may help bones mineralize properly, addressing the skeletal undermineralization that causes rickets and osteomalacia.^[8]

Clinical trials of INZ-701 have progressed through multiple phases. An initial Phase 1/2 study enrolled adult patients with ENPP1 Deficiency to assess safety, tolerability, and how the drug behaves in the body (pharmacokinetics) while also measuring biological markers that indicate whether the drug is having the desired effect (pharmacodynamics). Early results from the first three patients treated showed positive preliminary biomarker data, suggesting that INZ-701 successfully raised pyrophosphate levels in the blood. The safety profile in these initial patients was favorable, with the drug appearing to be generally well-tolerated.^[1]

Phase 1 clinical trials primarily focus on safety—determining whether an experimental treatment causes unacceptable side effects and identifying the appropriate dose range to use in later studies. Phase 2 trials expand testing to more patients and focus on whether the treatment actually works to improve disease markers or symptoms. Phase 3 trials are large, controlled studies that compare the new treatment against current standard care (or placebo if no effective treatment exists) to definitively prove whether the new therapy is beneficial and safe enough for regulatory approval.^[15]

Following the early adult study, the clinical development program for INZ-701 expanded to include infants and children, the populations most severely affected by ENPP1 Deficiency. The ENERGY study (Study INZ701-104) is a Phase 1b trial specifically designed for infants from birth up to one year of age who have confirmed ENPP1 Deficiency or a related condition called ABCC6 Deficiency. This study aims to evaluate whether INZ-701 is safe and well-tolerated in this vulnerable age group while also collecting information about how the drug is processed in infant bodies and whether it successfully raises pyrophosphate levels. The ENERGY study is actively recruiting patients.^[12]

Another ongoing trial, the ENERGY 3 study (Study INZ701-106), has advanced to Phase 3 and focuses on children aged 1 to 12 years with ENPP1 Deficiency. This pivotal trial is designed to definitively assess whether INZ-701 is effective in improving clinically meaningful outcomes in children while continuing to monitor safety. Phase 3 represents the final step before seeking regulatory approval from agencies like the U.S. Food and Drug Administration or the European Medicines Agency. The fact that INZ-701 has reached Phase 3 testing indicates that earlier studies provided sufficient evidence of potential benefit and acceptable safety to justify this larger, definitive trial.^[13]

For patients who have participated in earlier clinical trials and wish to continue receiving INZ-701, the ADAPT study (Study INZ701-304) provides long-term access. This Phase 2 extension study allows patients with either ENPP1 Deficiency or ABCC6 Deficiency who previously enrolled in other INZ-701 trials to keep receiving the treatment while researchers gather additional long-term safety data. This type of study is important because genetic diseases like ENPP1 Deficiency are lifelong conditions, and understanding how a treatment performs over many years is essential.^[13]

The mechanism by which INZ-701 works is relatively straightforward in concept but represents a sophisticated biologic therapy. The drug consists of a modified version of the human ENPP1 protein produced using recombinant DNA technology in laboratory cell cultures. Once infused into a patient’s bloodstream, INZ-701 circulates through the body and attaches to cell surfaces where the natural enzyme would normally reside. There, it carries out the same biochemical reactions, breaking down ATP to produce pyrophosphate and helping maintain the proper balance between mineralization and calcification throughout the body.^[11]

Patients enrolled in these clinical trials receive INZ-701 through intravenous infusion, meaning the drug is delivered directly into a vein over a period of time, typically in a hospital or clinical setting. The exact dosing schedule varies by study but generally involves regular infusions—potentially weekly or every other week—to maintain therapeutic levels of the enzyme in the bloodstream. Researchers carefully monitor participants through blood tests that measure pyrophosphate levels, markers of bone formation and breakdown, kidney function, and calcium metabolism, along with imaging studies to assess whether calcification is stabilizing or improving and whether bone density is changing.^[12]

Preliminary results from completed studies have shown encouraging signs. In adult patients, INZ-701 successfully raised plasma pyrophosphate levels toward or into the normal range, demonstrating that the enzyme replacement is biochemically active. Some patients showed improvements in clinical parameters such as pain levels and mobility, although formal efficacy assessments await completion of the larger Phase 3 trials. The safety profile observed so far suggests that enzyme replacement therapy is generally well-tolerated, with most side effects being mild to moderate. Common reactions include infusion-related effects such as headache, nausea, or injection site reactions, typical of many intravenous biologic therapies.^[1]

Beyond INZ-701, researchers continue to explore the fundamental biology of ENPP1 Deficiency to identify additional therapeutic targets. Understanding exactly how the lack of ENPP1 enzyme leads to the paradoxical situation of too much calcium in soft tissues while simultaneously causing weak, undermineralized bones could reveal new approaches. Some research focuses on downstream effects, such as why patients with ENPP1 Deficiency develop elevated levels of a hormone called FGF23 that causes kidneys to waste phosphate. If the mechanism linking ENPP1 deficiency to FGF23 elevation could be blocked, it might improve bone outcomes without risking increased soft tissue calcification.^[11]

The infrastructure supporting these clinical trials is substantial. Trial sites are typically major academic medical centers with expertise in rare diseases, pediatric genetics, metabolic disorders, and bone diseases. Investigators include specialists in endocrinology, cardiology, genetics, and nephrology who work together to comprehensively evaluate each participant. Patient advocacy groups like GACI Global partner with researchers and pharmaceutical companies to help families learn about trials, provide support throughout participation, and ensure that research addresses the questions most important to patients and families.^[7]

Parallel to therapeutic trials, observational studies are underway to better characterize the natural history of ENPP1 Deficiency—how the disease evolves over time in patients who receive only standard supportive care. The PROPEL registry (NCT06302439) is a global, multicenter prospective observational study that systematically collects clinical information from up to 1,000 participants over ten years. This registry gathers data on when symptoms appear, how calcification and clinical complications progress, and how the disease affects quality of life based on patient-reported outcomes. Such natural history data is invaluable for designing better clinical trials, understanding which outcomes matter most to patients, and providing families with realistic expectations about disease progression.^[7]

Understanding the genetic prevalence of ENPP1 Deficiency helps researchers estimate how many patients might benefit from new therapies. Recent genetic database analyses suggest the condition may be more common than previously thought, with an estimated prevalence of approximately 1 in 64,000 pregnancies. This figure is more than triple earlier estimates and indicates that many cases likely go undiagnosed. The findings suggest that expanding genetic testing, particularly in non-European populations where carrier rates may be higher, could identify more affected individuals who might benefit from emerging treatments.^[4]

Most Common Treatment Methods

• Supportive Cardiovascular Care
  • Medications to control blood pressure and manage heart failure in infants with severe arterial calcification
  • Cardiac monitoring and intervention for life-threatening complications such as myocardial infarction and stroke
  • Intensive care support for infants with cardiac or multiorgan failure
• Phosphate and Vitamin D Supplementation
  • Oral phosphate supplements given multiple times daily to address hypophosphatemia in patients with rickets
  • Active vitamin D (calcitriol) to support phosphate absorption and bone mineralization
  • Careful monitoring of blood phosphate, calcium, and kidney function to avoid worsening soft tissue calcification
• Physical Therapy and Rehabilitation
  • Exercise programs to strengthen muscles and maintain joint flexibility across all age groups
  • Gait training and mobility support for children with bone deformities
  • Fall prevention strategies and independence training for adults with progressive skeletal complications
• Pain Management
  • Pain medications for chronic bone and joint pain in adults and older children
  • Physical modalities such as heat, ice, and therapeutic exercises to reduce discomfort
  • Interventions to address immobility and functional limitations caused by pain
• Surgical Interventions
  • Orthopedic procedures to correct severe bone deformities affecting mobility
  • Joint surgeries for patients with advanced calcification causing significant functional impairment
  • Hearing devices or procedures for progressive hearing loss
• Enzyme Replacement Therapy (Investigational)
  • INZ-701, a recombinant ENPP1 enzyme given by intravenous infusion in clinical trials
  • Designed to restore pyrophosphate production and address both soft tissue calcification and skeletal undermineralization
  • Currently being studied in Phase 1b to Phase 3 trials across different age groups
  • Preliminary results show successful elevation of plasma pyrophosphate levels with favorable safety profiles
• Multidisciplinary Monitoring
  • Regular follow-up with cardiologists to monitor cardiovascular status and arterial calcification progression
  • Endocrinology assessments for bone health, growth, and mineral metabolism
  • Audiology evaluations to detect and manage progressive hearing loss
  • Nephrology monitoring for kidney function and complications related to abnormal mineral handling